Market Closed -
Hong Kong S.E.
01:39:00 03/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
29.8
HKD
|
-0.67%
|
|
-2.30%
|
-20.43%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
39,166
|
31,092
|
36,877
|
28,299
|
24,763
|
-
|
-
|
Enterprise Value (EV)
1 |
36,595
|
29,387
|
34,808
|
28,741
|
25,771
|
26,814
|
27,746
|
P/E ratio
|
-56.1
x
|
111
x
|
-27.2
x
|
-11.9
x
|
-13.1
x
|
-22
x
|
-57.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
21.8
x
|
48
x
|
26.1
x
|
14.6
x
|
9.49
x
|
7.49
x
|
EV / Revenue
|
-
|
20.6
x
|
45.3
x
|
26.5
x
|
15.2
x
|
10.3
x
|
8.39
x
|
EV / EBITDA
|
-60.4
x
|
80.3
x
|
-43.8
x
|
-21.7
x
|
-28.2
x
|
-40.9
x
|
256
x
|
EV / FCF
|
-33.2
x
|
-83.6
x
|
-17.2
x
|
-12.2
x
|
-18.4
x
|
-36.1
x
|
-134
x
|
FCF Yield
|
-3.02%
|
-1.2%
|
-5.8%
|
-8.2%
|
-5.44%
|
-2.77%
|
-0.75%
|
Price to Book
|
10.9
x
|
8.98
x
|
3.64
x
|
5.34
x
|
5.17
x
|
6.76
x
|
8.57
x
|
Nbr of stocks (in thousands)
|
4,89,837
|
4,89,837
|
5,39,197
|
5,38,532
|
5,37,914
|
-
|
-
|
Reference price
2 |
79.96
|
63.47
|
51.14
|
34.04
|
27.61
|
27.61
|
27.61
|
Announcement Date
|
26/03/21
|
20/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1,426
|
767.8
|
1,083
|
1,690
|
2,609
|
3,307
|
EBITDA
1 |
-
|
-605.6
|
365.8
|
-794.1
|
-1,322
|
-915.4
|
-655.2
|
108.4
|
EBIT
1 |
-
|
-668.6
|
281.6
|
-980.9
|
-1,502
|
-907.6
|
-215.3
|
84.5
|
Operating Margin
|
-
|
-
|
19.74%
|
-127.76%
|
-138.65%
|
-53.69%
|
-8.25%
|
2.56%
|
Earnings before Tax (EBT)
1 |
-
|
-697.8
|
276.3
|
-998.8
|
-1,511
|
-1,152
|
-683.4
|
-279.7
|
Net income
1 |
-430.3
|
-697.8
|
276.3
|
-998.8
|
-1,511
|
-1,148
|
-687.3
|
-270.7
|
Net margin
|
-
|
-
|
19.37%
|
-130.09%
|
-139.55%
|
-67.89%
|
-26.35%
|
-8.19%
|
EPS
2 |
-
|
-1.425
|
0.5700
|
-1.880
|
-2.860
|
-2.113
|
-1.254
|
-0.4787
|
Free Cash Flow
1 |
-
|
-1,104
|
-351.4
|
-2,019
|
-2,356
|
-1,402
|
-743.4
|
-207
|
FCF margin
|
-
|
-
|
-24.64%
|
-263%
|
-217.51%
|
-82.91%
|
-28.5%
|
-6.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/10/20
|
26/03/21
|
20/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 S2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
---|
Net sales
|
-
|
1,397
|
-
|
-
|
198.1
|
419
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
720.3
|
-
|
-
|
-
|
-509.7
|
-
|
Net income
1 |
-444
|
-
|
-489.1
|
-199.1
|
-
|
-509.7
|
-323.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-121.65%
|
-
|
EPS
2 |
-0.9100
|
-
|
-0.9600
|
-0.3600
|
-
|
-
|
-0.6000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/08/21
|
20/02/22
|
30/08/22
|
27/10/22
|
27/02/23
|
27/02/23
|
27/04/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
442
|
1,008
|
2,051
|
2,983
|
Net Cash position
1 |
-
|
2,571
|
1,704
|
2,069
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.3342
x
|
-1.101
x
|
-3.13
x
|
27.52
x
|
Free Cash Flow
1 |
-
|
-1,104
|
-351
|
-2,019
|
-2,356
|
-1,402
|
-743
|
-207
|
ROE (net income / shareholders' equity)
|
-
|
-41.5%
|
7.85%
|
-23.7%
|
-35.5%
|
-38.9%
|
-37.4%
|
-25.1%
|
ROA (Net income/ Total Assets)
|
-
|
-29%
|
6.68%
|
-19.6%
|
-26.2%
|
-19.9%
|
-11.9%
|
-6.48%
|
Assets
1 |
-
|
2,403
|
4,138
|
5,090
|
5,775
|
5,770
|
5,789
|
4,177
|
Book Value Per Share
2 |
-
|
7.340
|
7.070
|
14.00
|
6.380
|
5.340
|
4.080
|
3.220
|
Cash Flow per Share
2 |
-
|
-1.620
|
0.5400
|
-2.380
|
-
|
-1.740
|
-0.5100
|
-0.1000
|
Capex
1 |
-
|
443
|
615
|
756
|
853
|
516
|
332
|
242
|
Capex / Sales
|
-
|
-
|
43.12%
|
98.41%
|
78.74%
|
30.54%
|
12.73%
|
7.32%
|
Announcement Date
|
28/10/20
|
26/03/21
|
20/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Last Close Price
27.61
CNY Average target price
39.69
CNY Spread / Average Target +43.76% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.43% | 3.42B | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|